Sudoscan to Participate in the 4th Multidisciplinary French-Speaking Conference on Amyloidosis
Sudoscan is pleased to announce its participation in the 4th Multidisciplinary French-Speaking Conference on Amyloidosis, taking place on December 17th, 2025 at the Fondation Biermans-Lapôtre, 9A Boulevard Jourdan, 75014 Paris, in a hybrid format combining in-person and virtual attendance.
About the Congress
The Multidisciplinary French-Speaking Conference on Amyloidosis is the annual gathering of leading experts involved in the diagnosis, treatment, and multidisciplinary management of amyloidosis. The event is organized by the French reference centers for amyloidosis together with the Association Française contre l’Amylose, bringing together cardiologists, neurologists, internists, nephrologists, hematologists, biologists, general practitioners, and paramedical professionals.
This year’s edition will explore several major topics, including the role of artificial intelligence in diagnosis, new therapeutic strategies, the involvement of paramedical teams in patient pathways, updates on rare forms of amyloidosis, and the emergence of immunotherapy and bispecific treatments.
If you want to learn more about this year’s program, click here.
Why Sudoscan fits the congress’ mission
Amyloidosis can affect small nerve fibers and autonomic function—in particular through amyloid neuropathy. In this context, Sudoscan’s technology provides a relevant, non-invasive solution for early clinical evaluation. Indeed, Sudoscan is a CE-marked, FDA-cleared Class IIa medical device designed to evaluate sudomotor function, a proxy for small fiber and autonomic nerve integrity.
Its key advantages include:
• Fast testing: results in under three minutes with no patient preparation.
• Non-invasive and painless: suitable for repeated assessments and routine follow-up.
• Quantitative and reproducible metrics: independent of operator technique, providing consistent data across visits and sites.
For clinicians managing amyloidosis, Sudoscan offers a sensitive, practical solution to identify early small fiber involvement, complement other diagnostic tools, and support longitudinal monitoring.
For more studies on the efficacy of Sudoscan’s technology in neurological diseases, including amyloidosis, visit our publications page.
Meet Sudoscan at the 2025 Multidisciplinary French-Speaking Conference on Amyloidosis
We invite all congress participants-physicians, researchers, and paramedical professionals to meet the Sudoscan team during the event. Attendees will have the opportunity to:
• See live demonstrations of the Sudoscan device
• Discuss integration into diagnostic and follow-up care pathways for amyloidosis patients
• Explore the value of sudomotor testing in assessing small fiber and autonomic dysfunction
For more details about the congress and registration, please visit the official website of the congress.
